What is the market price of Tarlatamab-Imdelltra?

Tarlatamab-Imdelltra is a new immunotherapy drug approved by the US FDA in May 2024. It is mainly used for patients with extensive-stage small cell lung cancer (ES-SCLC) who have progressed during or after platinum-based chemotherapy. Its clinical application value is mainly reflected in the novel mechanism and the particularity of the treatment population. Patients with small cell lung cancer often achieve certain results with initial treatment, but due to extremely high drug resistance and recurrence rates, traditional drug options are limited, resulting in poor survival prognosis. As the first DLL3-directed bispecific T cell engager, talatumumab brings new hope for survival to this group by activating the patient's own T cells to kill tumor cells.

At the application level, talatumumab is regarded as a useful complement to traditional chemotherapy and immunotherapy. It can accurately identify DLL3 molecules on the surface of tumor cells and trigger immune attack with the help of CD3 activation mechanism. This mode of action means that it can not only produce responses in partially drug-resistant patients, but may also change the overall treatment landscape of small cell lung cancer in the future. At present, relevant research is still exploring the potential of this drug in combination regimens, which is expected to further expand its application scenarios.

As for the market price, the overseas market specifications of talatumumab are1mg and 10mg respectively, and the selling price is approximately 20,000 to 100,000 yuan. Due to its innovative attributes and patent protection, there is currently no imitation version, which is relatively expensive and brings a certain financial burden to patients. In addition, the drug has not yet been launched in China and has not been included in the medical insurance reimbursement system. Domestic patients often need to purchase drugs through cross-border channels if they need to use it, which undoubtedly increases the difficulty of treatment.

In the long term, with the gradual promotion of the international market and the advancement of the drug patent period, the cost of talatumumab is expected to gradually decrease. Once it is approved for marketing in China and entered into the medical insurance catalog, it will greatly improve patients' medication accessibility and affordability.

Reference materials:https://www.drugs.com/mtm/tarlatamab.html